Priovant’s Brepocitinib Secures FDA Priority Review with Q3 2026 PDUFA Date
FDA has accepted Priovant’s NDA for brepocitinib in dermatomyositis with a PDUFA action date in Q3 2026 and a planned U.S. launch by end-September 2026. The Priority Review designation follows positive Phase 3 VALOR results, including statistically significant myositis Total Improvement Score gains at Week 52 in 241 patients.
1. FDA Acceptance and Priority Review
The FDA has accepted Priovant’s NDA for brepocitinib in dermatomyositis and granted Priority Review status. A PDUFA target action date is set for the third quarter of 2026, with Priovant aiming for a U.S. launch by the end of September 2026 if approved.
2. Phase 3 VALOR Study Highlights
The global VALOR trial enrolled 241 patients across 90 sites and demonstrated that brepocitinib 30 mg achieved statistically significant improvement on the myositis Total Improvement Score at Week 52 versus placebo. Efficacy benefits appeared as early as Week 4 and were sustained through the 52-week treatment period.
3. Safety and Tolerability Findings
Brepocitinib 30 mg showed a safety profile in line with approved JAK/TYK2 inhibitors, with serious infections manageable through medical intervention. Rates of new or recurrent malignancy, cardiovascular events, and thromboembolic events were lower in the brepocitinib arm compared to placebo.
4. Commercial and Clinical Outlook
If approved, brepocitinib would become the first targeted therapy for dermatomyositis, addressing significant unmet need and reducing reliance on chronic high-dose steroids. Successful launch could establish a new revenue stream for Priovant and reshape treatment standards for this patient population.